Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B

Chia Yun Wu; Liang Tsai Hsiao; Tzeon Jye Chiou; Jyh Pyng Gau; Jin Hwang Liu; Yuan Bin Yu; Yi Tsui Wu; Chia Jen Liu; Yu Chung Huang; Man Hsin Hung; Po Min Chen; Yi Hsiang Huang; Cheng Hwai Tzeng

doi:10.3109/10428194.2014.991922

Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B

Chia Yun Wu, Liang Tsai Hsiao, Tzeon Jye Chiou, Jyh Pyng Gau, Jin Hwang Liu, Yuan Bin Yu, Yi Tsui Wu, Chia Jen Liu, Yu Chung Huang, Man Hsin Hung, Po Min Chen, Yi Hsiang Huang, Cheng Hwai Tzeng^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Reactivation of hepatitis B virus (HBV) following rituximab (R)-containing chemotherapy for lymphoma is a major concern, and risk factors remain to be defined. We enrolled 190 patients diagnosed with diffuse large B-cell lymphoma (DLBCL) and resolved hepatitis B, receiving first-line R-CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone)-based regimens. Twenty-seven patients (14.2%) developed HBV reactivation during a median follow-up of 23.6 months. Two independent risk factors were identified: cycles of rituximab > 8 (hazard ratio [HR], 2.797; 95% confidence interval [CI], 1.184-6.612) and lymphocyte/monocyte ratio (LMR) < 2.50 (HR, 2.733; 95% CI, 1.122-6.657). Two-year overall survival in patients with or without HBV reactivation was 53.8% vs. 77.6% (p = 0.025). Regarding the negative impact on clinical outcome, patients at "super high risk" of HBV reactivation, including those receiving more than eight cycles of R and having low LMR at diagnosis, may warrant first priority for antiviral prophylaxis.

Original language	English
Pages (from-to)	2357-2364
Number of pages	8
Journal	Leukemia and Lymphoma
Volume	56
Issue number	8
DOIs	https://doi.org/10.3109/10428194.2014.991922
State	Published - 3 Aug 2015

Keywords

HBV reactivation
diffuse large B-cell lymphoma
lymphocyte/monocyte ratio
resolved hepatitis B
rituximab

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/10428194.2014.991922

Cite this

Wu, C. Y., Hsiao, L. T., Chiou, T. J., Gau, J. P., Liu, J. H., Yu, Y. B., Wu, Y. T., Liu, C. J., Huang, Y. C., Hung, M. H., Chen, P. M., Huang, Y. H., & Tzeng, C. H. (2015). Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B. Leukemia and Lymphoma, 56(8), 2357-2364. https://doi.org/10.3109/10428194.2014.991922

@article{ae5efef6ba8a4774afcc27a90fe463fd,

title = "Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B",

abstract = "Reactivation of hepatitis B virus (HBV) following rituximab (R)-containing chemotherapy for lymphoma is a major concern, and risk factors remain to be defined. We enrolled 190 patients diagnosed with diffuse large B-cell lymphoma (DLBCL) and resolved hepatitis B, receiving first-line R-CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone)-based regimens. Twenty-seven patients (14.2%) developed HBV reactivation during a median follow-up of 23.6 months. Two independent risk factors were identified: cycles of rituximab > 8 (hazard ratio [HR], 2.797; 95% confidence interval [CI], 1.184-6.612) and lymphocyte/monocyte ratio (LMR) < 2.50 (HR, 2.733; 95% CI, 1.122-6.657). Two-year overall survival in patients with or without HBV reactivation was 53.8% vs. 77.6% (p = 0.025). Regarding the negative impact on clinical outcome, patients at {"}super high risk{"} of HBV reactivation, including those receiving more than eight cycles of R and having low LMR at diagnosis, may warrant first priority for antiviral prophylaxis.",

keywords = "HBV reactivation, diffuse large B-cell lymphoma, lymphocyte/monocyte ratio, resolved hepatitis B, rituximab",

author = "Wu, {Chia Yun} and Hsiao, {Liang Tsai} and Chiou, {Tzeon Jye} and Gau, {Jyh Pyng} and Liu, {Jin Hwang} and Yu, {Yuan Bin} and Wu, {Yi Tsui} and Liu, {Chia Jen} and Huang, {Yu Chung} and Hung, {Man Hsin} and Chen, {Po Min} and Huang, {Yi Hsiang} and Tzeng, {Cheng Hwai}",

note = "Publisher Copyright: {\textcopyright} 2015 {\textcopyright} 2015 Informa UK, Ltd.",

year = "2015",

month = aug,

day = "3",

doi = "10.3109/10428194.2014.991922",

language = "English",

volume = "56",

pages = "2357--2364",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "8",

}

Wu, CY, Hsiao, LT, Chiou, TJ, Gau, JP, Liu, JH, Yu, YB, Wu, YT, Liu, CJ, Huang, YC, Hung, MH, Chen, PM, Huang, YH & Tzeng, CH 2015, 'Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B', Leukemia and Lymphoma, vol. 56, no. 8, pp. 2357-2364. https://doi.org/10.3109/10428194.2014.991922

Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B. / Wu, Chia Yun; Hsiao, Liang Tsai; Chiou, Tzeon Jye et al.
In: Leukemia and Lymphoma, Vol. 56, No. 8, 03.08.2015, p. 2357-2364.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B

AU - Wu, Chia Yun

AU - Hsiao, Liang Tsai

AU - Chiou, Tzeon Jye

AU - Gau, Jyh Pyng

AU - Liu, Jin Hwang

AU - Yu, Yuan Bin

AU - Wu, Yi Tsui

AU - Liu, Chia Jen

AU - Huang, Yu Chung

AU - Hung, Man Hsin

AU - Chen, Po Min

AU - Huang, Yi Hsiang

AU - Tzeng, Cheng Hwai

PY - 2015/8/3

Y1 - 2015/8/3

N2 - Reactivation of hepatitis B virus (HBV) following rituximab (R)-containing chemotherapy for lymphoma is a major concern, and risk factors remain to be defined. We enrolled 190 patients diagnosed with diffuse large B-cell lymphoma (DLBCL) and resolved hepatitis B, receiving first-line R-CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone)-based regimens. Twenty-seven patients (14.2%) developed HBV reactivation during a median follow-up of 23.6 months. Two independent risk factors were identified: cycles of rituximab > 8 (hazard ratio [HR], 2.797; 95% confidence interval [CI], 1.184-6.612) and lymphocyte/monocyte ratio (LMR) < 2.50 (HR, 2.733; 95% CI, 1.122-6.657). Two-year overall survival in patients with or without HBV reactivation was 53.8% vs. 77.6% (p = 0.025). Regarding the negative impact on clinical outcome, patients at "super high risk" of HBV reactivation, including those receiving more than eight cycles of R and having low LMR at diagnosis, may warrant first priority for antiviral prophylaxis.

AB - Reactivation of hepatitis B virus (HBV) following rituximab (R)-containing chemotherapy for lymphoma is a major concern, and risk factors remain to be defined. We enrolled 190 patients diagnosed with diffuse large B-cell lymphoma (DLBCL) and resolved hepatitis B, receiving first-line R-CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone)-based regimens. Twenty-seven patients (14.2%) developed HBV reactivation during a median follow-up of 23.6 months. Two independent risk factors were identified: cycles of rituximab > 8 (hazard ratio [HR], 2.797; 95% confidence interval [CI], 1.184-6.612) and lymphocyte/monocyte ratio (LMR) < 2.50 (HR, 2.733; 95% CI, 1.122-6.657). Two-year overall survival in patients with or without HBV reactivation was 53.8% vs. 77.6% (p = 0.025). Regarding the negative impact on clinical outcome, patients at "super high risk" of HBV reactivation, including those receiving more than eight cycles of R and having low LMR at diagnosis, may warrant first priority for antiviral prophylaxis.

KW - HBV reactivation

KW - diffuse large B-cell lymphoma

KW - lymphocyte/monocyte ratio

KW - resolved hepatitis B

KW - rituximab

UR - http://www.scopus.com/inward/record.url?scp=84942411386&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.991922

DO - 10.3109/10428194.2014.991922

M3 - Article

C2 - 25459444

AN - SCOPUS:84942411386

SN - 1042-8194

VL - 56

SP - 2357

EP - 2364

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 8

ER -

Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this